Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy

Publisher： Karger

E-ISSN： 1423-0097|136|3|239-249

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.136, Iss.3, 2005-03, pp. : 239-249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterization of Recombinant Bet v 4, a Birch Pollen Allergen with Two EF–Hand Calcium–Binding Domains

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 304-305

Karger

Access to resources Recommend Favorite

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients

By  

ALLERGY, Vol. 70, Iss. 7, 2015-07 ,pp. : 795-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Can serum white birch (Betula verrucosa) pollen antigen (Bet v 1) immunoglobulin E measurement distinguish between sensitization and allergy?

By  

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, Vol. 5, Iss. 12, 2015-12 ,pp. : 1151-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

By  

International Archives of Allergy and Immunology, Vol. 126, Iss. 1, 2001-10 ,pp. : 68-77

Karger

Access to resources Recommend Favorite